SWM
DNTH icon

SeaCrest Wealth Management’s Dianthus Therapeutics DNTH Stock Holding History

SeaCrest Wealth Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,949
Closed -$369K – 696
2021
Q1 		$369K Buy
+1,949
New +$328K 0.05% 405
2019
Q2 		– Sell
-25
Closed -$7K – 845
2019
Q1 		$7K Hold
25
– – ﹤0.01% 1620
2018
Q4 		$2K Sell
25
-25
-50% -$3.41K ﹤0.01% 1899
2018
Q3 		$10K Sell
50
-13
-21% -$2.74K ﹤0.01% 1647
2018
Q2 		$14K Buy
+63
New +$14.2K ﹤0.01% 1487

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

SeaCrest Wealth Management's DNTH Position: Q2 2021 in Review

SeaCrest Wealth Management sold out of Dianthus Therapeutics (DNTH) in Q2 2021, closing a stake of 1,949 shares — an estimated $369K sold.

SeaCrest Wealth Management first reported a position in DNTH in Q2 2018 and held it in 5 quarters. The position peaked at $369K in Q1 2021. 97 funds tracked by Wall St. Rank hold DNTH as of Q2 2021.

  • SeaCrest Wealth Management reported no remaining Dianthus Therapeutics position as of Q2 2021 after selling out during the quarter.
  • SeaCrest Wealth Management sold 1,949 Dianthus Therapeutics shares in Q2 2021, an estimated $369K.
  • SeaCrest Wealth Management first reported a position in Dianthus Therapeutics in Q2 2018 and held it in 5 quarters.
  • SeaCrest Wealth Management's Dianthus Therapeutics position peaked at $369K in Q1 2021.
  • 97 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2021.

Based on SeaCrest Wealth Management's 13F filing for Q2 2021, filed 12 Aug 2021.